Press release
Tenosynovial Giant Cell Tumors Clinical Trial Pipeline Accelerates as 5+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
Explore our latest breakthroughs in Tenosynovial Giant Cell Tumors Research @ Tenosynovial Giant Cell Tumors Pipeline Outlook [https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Tenosynovial Giant Cell Tumors Pipeline Report
* On April 16, 2026, Merck Healthcare KGaA initiated a phase 2 study is to assess the tolerability, pharmacokinetics (PK), efficacy, and safety of pimicotinib in Japanese participants with TGCT in two cohorts: Safety Run-in and Expansion.
* DelveInsight's Tenosynovial Giant Cell Tumors pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Tenosynovial Giant Cell Tumors treatment.
* The leading Tenosynovial Giant Cell Tumors Companies such as AmMax Bio Inc., Deciphera Pharmaceuticals, SynOx Therapeutics, Abbisko Therapeutics Co, Ltd., Hutchison Medipharma Limited, Elixiron Immunotherapeutics and others.
* Promising Tenosynovial Giant Cell Tumors Pipeline Therapies such as Pexidartinib, Vimseltinib, Pimicotinib(ABSK021), FPA008, Nilotinib, AMB-05X, Emactuzumab, MCS110 and others.
Download for updates and be a part of the revolution in oncology care @ Tenosynovial Giant Cell Tumors Clinical Trials Assessment [https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Tenosynovial Giant Cell Tumors Overview
Tenosynovial giant cell tumors are a group of generally benign intra-articular and soft tissue tumors with common histologic features. They can be roughly divided into localized and diffuse types. Localized types include giant cell tumors of tendon sheath and localized pigmented villonodular synovitis, whereas diffuse types encompass conventional pigmented villonodular synovitis and diffuse-type giant cell tumor. Localized tumors are generally indolent, whereas diffuse tumors are locally aggressive. Recent developments indicate that tenosynovial giant cell tumors are clonal neoplastic tumors driven by overexpression of CSF1. TSGCT is a benign tumor that arises from the tendon sheath in most cases. However, in a few cases, the diffuse type has been documented to lung metastases. The purpose of this case report was to confirm that TSGCT, localized type, can become malignant, and spread to the lungs.
Tenosynovial Giant Cell Tumors Emerging Drugs Profile
* Vimseltinib: Deciphera Pharmaceuticals
Vimseltinib is an investigational, orally administered, potent and highly selective switch-control kinase inhibitor of CSF1R. Vimseltinib was discovered using our proprietary drug discovery platform and was designed to selectively bind to the CSF1R switch pocket. Vimseltinib has demonstrated encouraging preliminary efficacy and safety data in patients with TGCT. It is currently being evaluated in Phase III clinical trial to treat patients with Tenosynovial Giant Cell Tumors. The MOTION Phase III study is two-part, randomized, double-blind, placebo-controlled study of vimseltinib to assess the efficacy and safety in patients with symptomatic TGCT who are not amenable to surgery.
* EI-1071: Elixiron Immunotherapeutics
EI-1071 is a small-molecule drug that inhibits the tyrosine kinase activity of the Colony Stimulating Factor1 Receptor (CSF1R). EI1071 has a potentially best-in-class therapeutic index or potency-versus-toxicity profile, shows efficient blood-brain-barrier penetration and causes robust reduction of brain microglia in pre-clinical models. EI-1071 also reduces tumor-associated macrophage numbers and improves tumor control in cancer models. EI-1071 is being developed for the treatment of recurrent and/or diffuse Tenosynovial Giant Cell Tumors (TGCT), a debilitating disease of the joints driven by over-expression of CSF-1, for which a phase II trial is being planned to start in 2023.
The Tenosynovial Giant Cell Tumors Pipeline Report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Tenosynovial Giant Cell Tumors with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Tenosynovial Giant Cell Tumors Treatment.
* Tenosynovial Giant Cell Tumors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Tenosynovial Giant Cell Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Tenosynovial Giant Cell Tumors market.
Learn more about Tenosynovial Giant Cell Tumors Drugs opportunities in our groundbreaking research @ Tenosynovial Giant Cell Tumors Unmet Needs [https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Tenosynovial Giant Cell Tumors Companies
AmMax Bio Inc., Deciphera Pharmaceuticals, SynOx Therapeutics, Abbisko Therapeutics Co, Ltd., Hutchison Medipharma Limited, Elixiron Immunotherapeutics and others.
Tenosynovial Giant Cell Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* intravenous
* Subcutaneous
* Topical.
Tenosynovial Giant Cell Tumors Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Stay informed about how we're transforming the future of oncology @ Tenosynovial Giant Cell Tumors Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Tenosynovial Giant Cell Tumors Pipeline Report
* Coverage- Global
* Tenosynovial Giant Cell Tumors Companies- AmMax Bio Inc., Deciphera Pharmaceuticals, SynOx Therapeutics, Abbisko Therapeutics Co, Ltd., Hutchison Medipharma Limited, Elixiron Immunotherapeutics and others.
* Promising Tenosynovial Giant Cell Tumors Pipeline Therapies- Pexidartinib, Vimseltinib, Pimicotinib(ABSK021), FPA008, Nilotinib, AMB-05X, Emactuzumab, MCS110 and others.
* Tenosynovial Giant Cell Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Tenosynovial Giant Cell Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Read the full details of Tenosynovial Giant Cell Tumors Pipeline on our website @ Tenosynovial Giant Cell Tumors Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Tenosynovial Giant Cell Tumors: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late Stage Products (Phase III)
* Vimseltinib: Deciphera Pharmaceuticals
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* AMB-05X: AmMax Bio, Inc.
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Tenosynovial Giant Cell Tumors Key Companies
* Tenosynovial Giant Cell Tumors Key Products
* Tenosynovial Giant Cell Tumors- Unmet Needs
* Tenosynovial Giant Cell Tumors- Market Drivers and Barriers
* Tenosynovial Giant Cell Tumors- Future Perspectives and Conclusion
* Tenosynovial Giant Cell Tumors Analyst Views
* Tenosynovial Giant Cell Tumors Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=tenosynovial-giant-cell-tumors-clinical-trial-pipeline-accelerates-as-5-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/tenosynovial-giant-cell-tumors-tsgcts-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Tenosynovial Giant Cell Tumors Clinical Trial Pipeline Accelerates as 5+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight here
News-ID: 4495903 • Views: …
More Releases from ABNewswire
Autosomal Dominant Polycystic Kidney Disease Clinical Trial Pipeline Expands as …
DelveInsight's "Autosomal Dominant Polycystic Kidney Disease Pipeline Insight 2026" report provides comprehensive insights about 13+ companies and 14+ pipeline drugs in the Autosomal Dominant Polycystic Kidney Disease pipeline landscape. It covers the Autosomal Dominant Polycystic Kidney Disease Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Autosomal Dominant Polycystic Kidney Disease Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further…
Myasthenia Gravis Clinical Trial Pipeline Shows Potential with Active Contributi …
DelveInsight's, "Myasthenia Gravis Pipeline Insight 2026" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Myasthenia Gravis pipeline landscape. It covers the Myasthenia Gravis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myasthenia Gravis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in…
Non-Alcoholic Steatohepatitis Pipeline Set for Transformational Expansion by 202 …
Key Non-Alcoholic Steatohepatitis (NASH) Companies include Novo Nordisk, Viking Therapeutics, Inventiva Pharma, GlaxoSmithKline, Haisco Pharmaceutical Group, and others
The Non-Alcoholic Steatohepatitis (NASH) therapeutic landscape is entering a pivotal phase of innovation and clinical acceleration, driven by an expanding pipeline and increasing scientific understanding of disease biology. Companies such as Novo Nordisk, Viking Therapeutics, Inventiva Pharma, GlaxoSmithKline, and Haisco Pharmaceutical Group are at the forefront of reshaping the future of NASH treatment…
STAT Inhibitors Pipeline Set for Breakthrough Innovation by 2026 with 22+ Therap …
Key STAT Inhibitors Companies include Tvardi Therapeutics, Kymera Therapeutics, Recludix Pharma, Enanta Pharmaceuticals, Moleculin, Purple Biotech, LEO Pharma, JW Pharmaceutical, KAKEN PHARMACEUTICAL, C4XD Holdings, and others
The STAT inhibitors therapeutic landscape is undergoing a significant transformation, driven by rapid scientific advancements and increasing clinical activity across oncology and immunology indications. Companies such as Tvardi Therapeutics, Kymera Therapeutics, Inc., Recludix Pharma, Enanta Pharmaceuticals, Moleculin, Inc., Purple Biotech, LEO Pharma A/S, JW Pharmaceutical,…
More Releases for Tenosynovial
Tenosynovial Giant Cell Tumors Market to Expand Significantly by 2034, States De …
DelveInsight's "Tenosynovial Giant Cell Tumors Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Tenosynovial Giant Cell Tumors, historical and forecasted epidemiology as well as the Tenosynovial Giant Cell Tumors market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Tenosynovial Giant Cell Tumors market outlook, drug uptake, treatment scenario and epidemiology trends, Click…
Tenosynovial Giant Cell Tumors Pipeline Outlook 2025: Clinical Trial Studies, EM …
DelveInsight's, "Tenosynovial Giant Cell Tumors Pipeline Insight 2025" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Tenosynovial Giant Cell Tumors pipeline landscape. It covers the Tenosynovial Giant Cell Tumors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Tenosynovial Giant Cell Tumors therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
Tenosynovial Giant Cell Tumors Market: Epidemiology, Pipeline Products, and Comp …
Daiichi Sankyo's TURALIO is the only FDA-approved Tenosynovial Giant Cell Tumors therapy. However, a significant number of patients still use an off-label treatment like imatinib due to TURALIO's problematic safety and tolerability profile.
Tenosynovial Giant Cell Tumors emerging therapies such as TURALIO (pexidartinib), Vimseltinib (DCC-3014), and others are expected to boost the Tenosynovial Giant Cell Tumors Market in the upcoming years.
DelveInsight has launched a new report on "Tenosynovial Giant Cell Tumors…
Tenosynovial Giant Cell Tumors Treatment Market 2034: EMA, PDMA, FDA Approval, C …
Tenosynovial Giant Cell Tumors Companies are Daiichi Sankyo Co., Ltd., Deciphera Pharmaceuticals, Abbisko Therapeutics, AmMax Bio, Inc., SynOx Therapeutics Limited, Abbisko Therapeutics, Five Prime Therapeutics, Novartis, and others.
(Albany, USA) DelveInsight's "Tenosynovial Giant Cell Tumors Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Tenosynovial Giant Cell Tumors, historical and forecasted epidemiology as well as the Tenosynovial Giant Cell Tumors market trends in the United States, EU4…
Tenosynovial Giant Cell Tumors Market to Exhibit Substantial Growth Rate During …
As per DelveInsight, the Tenosynovial Giant Cell Tumors therapeutics market is anticipated to grow in the coming years owing to the increasing incident population of TSGCTs and the launch of the emerging drug in the 7MM.
Companies across the globe are diligently working toward developing novel treatment therapies with a considerable amount of success over the years. Key players, such as AmMax Bio, Inc., Deciphera Pharmaceuticals LLC, and others, are actively…
Tenosynovial Giant Cell Tumors Market to Exhibit Substantial Growth Rate During …
As per DelveInsight, the Tenosynovial Giant Cell Tumors therapeutics market is anticipated to grow in the coming years owing to the increasing incident population of TSGCTs and the launch of the emerging drug in the 7MM.
Companies across the globe are diligently working toward developing novel treatment therapies with a considerable amount of success over the years. Key players, such as AmMax Bio, Inc., Deciphera Pharmaceuticals LLC, and others, are actively…
